**11.2 Level III evidence**


ISRS also had published a review of 49 full-text articles from January 1963 to December 2014. The 5-year progression-free survival (PFS) rates was 86–99% and 10-year PFS was 69–97%. The followings are recommendations for management of cavernous sinus (CS) meningioma in level III evidence [48]:


National Comprehensive Cancer Network (NCCN) also had proposed guidelines for CNS tumors. Radiotherapy is recommended in the following clinical scenarios with Level 2A evidence [49]:

